Bant Breen:
Bullfrog AI is a business focused on proprietary artificial intelligence aimed at improving biopharma clinical development success. Tell me a little bit more about the type of the specific type of work that Bullfrog AI is doing.
Vin Singh:
Keep in mind, that it takes 10 to 15 years, and one to $2 billion to develop a drug. A lot of time and a lot of money. What we want to do is insert ourselves in that process, whether it’s before clinical trials, human clinical trials, or maybe toward the end of that process, and use our technology to improve the chances of success. Our platform can look at genetic and nongenetic data, can find patterns, and relationships, and predict targets of interest of things through the clinical outcome or new drug targets and things like that. We’re here to improve those chances for success and accelerate that process as well.
Bant Breen:
Data in and of itself has been problematic to get structured correctly. How do you guys go about getting over that hurdle?
Vin Singh:
It’s always a challenge. I mean, when we get a proprietary data set, the upfront process, the data engineering, and the cleansing are the longest part of the process. What’s important for us is having subject matter experts that can help us with that process. What you’re saying is important. Because you put garbage in, you’re gonna get garbage out. If we want actionable insights, and we want some precision in the analysis, we have to make sure the data that’s going in is as error-free as possible. We have as much insight as possible upfront so that when we’re doing the analysis, we’re going through the iterations. Our findings mean something, and we can take action from there.
Bant Breen:
Tell me a little bit about who uses Bullfrog AI in your client companies?
Vin Singh:
There are companies across the spectrum in the biopharmaceutical space, but you bring up a good point because biopharma has been doing things the same way for many years. When you introduce something new like this, there’s an adoption curve. Everybody’s concerned about how we will impact whatever they’re used to doing for the past 50, 60, and 70 years. They don’t want it, even though they want to increase their chances of success. They’re scared to incorporate cutting-edge technologies. It is a conservative industry, from that perspective, even though they’re developing cutting-edge therapies. It’s sort of an interesting balance. Right now, we’re primarily working with smaller companies. I think the reason is typical, they’re developing one or two candidates, and they gotta get to the finish line, they only get one shot. Whereas Big Pharma’s failures are built into their model. They know they’re going to fail half the time, even though they’ve spent those billions of dollars. They fail, and they move on as part of it, and even then, they’re still incredibly successful. Right now, our focus is more on the smaller companies that need that edge.
Bant Breen:
Vin, thank you so much for being on UNCAGED today and we look forward to having you back.
To see the full interview on the Uncaged YouTube channel, go to:
